# Genmab: Phase 2 study closed enrollment, 543 enrolled (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Genmab |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) |
| NCT ID | NCT04663347 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Diffuse Large B-Cell Lymphoma; Follicular Lymphoma |
| Intervention types | drug, biological |
| Target enrollment | 543 |
| Site countries | United States, Australia, Belgium, Czechia, Denmark, Finland, France, Italy, Netherlands, Norway, Spain, Sweden |
| Posted | 2020-12-11 |
| Planned start | 2020-11-03 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 543 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04663347). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.